BUSINESS
    Ex-Takeda CEO Weber Joins Rakuten Medical as Vice Chairman
    September 10, 2026
    Rakuten Medical said on September 10 that former Takeda Pharmaceutical CEO Christophe Weber has joined its board as vice chairman as the biotech beefs up its leadership ranks to drive its R&D and US commercialization…

    LATEST

    MHLW to Weigh Survey Data, Past Approach for FY2027 Revision: Official
    September 10, 2026
    Japan’s new pharmaceutical management director Taku Ohara says market data from an upcoming drug price survey will be key to determining the scope of the FY2027 off-year price revision, with the approach used in the…
    Chuikyo Reps Back Greater Transparency, but Lean toward Broader CEA Price Cuts
    September 10, 2026
    Provider and payer members of a key reimbursement policy panel signaled support on September 9 for the broader use of Japan’s cost-effectiveness assessment (CEA) system to cut drug prices, even as both sides acknowledged the…
    3 Chugai Researchers Win Lasker Award for Hemlibra Discovery
    September 10, 2026
    Three Chugai Pharmaceutical researchers who led the discovery of the hemophilia A treatment Hemlibra (emicizumab) have won the Lasker-DeBakey Clinical Medical Research Award, one of the world’s most prestigious medical research prizes.The winners announced on…

    Chuikyo Debate on FY2026 Drug Pricing Reform

    Romiplate to See Steepest Cut in April Market Expansion Re-Pricing

    Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

    COMMENTARY

    As US Pushes Global Cost Rebalancing, Can Japan Answer with Drug Prices?
    By Ken Yoshino

    Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…

    COLUMN

    The One Mistake on Your Resume
    By Philip Carrigan

    We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…

    Drug Approval & Reimbursement in 2025

    Chuikyo OKs Listing of Novartis’ Pluvicto, Peak Sales Outlook at 42.1 Billion Yen

    Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

    Chuikyo Debate on Off-Year Drug Price Revisions

    MHLW Unveils New List Prices for FY2025 Revision; Stelara, Januvia Hit by PMP Return
    By Ken Yoshino

    The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

    Discussions on Next PMD Act Amendment

    Japan Cabinet Approves Bill to Amend PMD Act

    The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

    Drug Approval & Reimbursement in 2024

    Japan Approves Zepbound, Qalsody, and Lots More Drugs

    Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

    Chuikyo on FY2024 Reimbursement Reform

    Chuikyo OKs Outline of FY2024 Drug Pricing Reform; No Unprofitability Re-Pricing for 7%-Plus Price Gap

    Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

    NEWS CATEGORY

    REGULATORY

    BUSINESS

    ORGANIZATION

    ACADEMIA